Advertisement
"RITA is highly regarded as a leading, global supplier of specialtychemicals to the cosmetic and personal care industries", said BelindaTsao-Nivaggioli, Ph.D., CEO of Avicena. "This makes RITA an ideal partner todistribute our proprietary dermaceutical ingredients and to significantlyexpand our existing dermaceutical business."
Advertisement
"We are excited to have the opportunity to distribute Avicena'sscientifically based skin care ingredients", said Brian Goode, President ofRITA. "The industry continues to shift toward ingredients that are backed byproven science and achieve measurable skin benefits. Avicena's products fitwell into this growing trend."
ABOUT AVICENA'S DERMACEUTICAL BUSINESS
Avicena is leveraging its proprietary cellular energy technology tocommercialize therapeutic dermaceutical products, as well as proprietaryingredients and formulations. Avicena's scientifically based skin careingredients and formulations are designed to enhance the regeneration ofhealthier skin and to protect against the effects of aging, as well asoxidative and photo damage.
Avicena has developed Nurigene(TM), an advanced skin care regimen based onthe company's patented cell-nourishing technology which enhances optimalcellular regeneration and protection by providing critical nourishment to skincells. Clinical studies have demonstrated that Nurigene has significantanti-aging benefits, including improvements in skin cell turnover, skinfirmness, skin elasticity and the skin's ability to retain moisture.
Avicena currently supplies its patent-protected ingredients to leadingmanufacturers of dermaceutical and cosmeceutical products. Avicena is alsoactively researching and developing additional proprietary formulations tocomplement its current dermaceutical product portfolio.
ABOUT AVICENA
Avicena Group, Inc. is a Palo Alto, California-based late-stagebiotechnology company that develops central nervous system therapeutics forneurodegenerative diseases. The company's core technologies, supported by arobust intellectual property portfolio, have broad applications in bothpharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centerson rare neurological disorders (orphan diseases). The company is currentlyanalyzing data from its Phase IIb/III trial in ALS. In the near term, Avicenaintends to initiate a Phase III trial in Huntington's disease to accompany theongoing NIH Phase III trial in Parkinson's disease. Avicena's science is wellestablished and its products are safe and well tolerated. Unlike traditionalbiotechnology companies, Avicena's clinical programs are largely funded bygovernment and non-profit organizations. Avicena presently derives revenuefrom the sale of proprietary dermaceutical ingredients to skin caremanufacturers.
ABOUT RITA Corporation
Over the past 54 years, RITA Corporation has positioned itself as aleading supplier of specialty chemicals to the personal care industry.Headquartered in Crystal Lake, Illinois, RITA operates five wholly-owneddistribution centers across the United States and is represented byinternational agents on six continents. In addition to exclusivedistributorshi
